Swedbank AB Makes New Investment in Ionis Pharmaceuticals, Inc. $IONS

Posted by Brenda Bartman on May 28th, 2026

Swedbank AB purchased a new position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) during the 4th quarter, Holdings Channel reports. The fund purchased 27,253 shares of the company’s stock, valued at approximately $2,156,000.

Several other institutional investors have also added to or reduced their stakes in IONS. Golden State Wealth Management LLC raised its position in Ionis Pharmaceuticals by 198.4% in the third quarter. Golden State Wealth Management LLC now owns 376 shares of the company’s stock worth $25,000 after acquiring an additional 250 shares during the period. Quarry LP bought a new position in Ionis Pharmaceuticals in the third quarter worth approximately $38,000. Johnson Financial Group Inc. bought a new position in Ionis Pharmaceuticals in the third quarter worth approximately $44,000. Laurel Wealth Advisors LLC bought a new position in Ionis Pharmaceuticals in the fourth quarter worth approximately $47,000. Finally, Bayforest Capital Ltd raised its position in Ionis Pharmaceuticals by 608.4% in the fourth quarter. Bayforest Capital Ltd now owns 1,091 shares of the company’s stock worth $86,000 after acquiring an additional 937 shares during the period. 93.86% of the stock is currently owned by institutional investors.

Insider Activity at Ionis Pharmaceuticals

In related news, EVP Kyle Jenne sold 37,277 shares of the firm’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $75.85, for a total transaction of $2,827,460.45. Following the completion of the transaction, the executive vice president directly owned 11,714 shares of the company’s stock, valued at approximately $888,506.90. This trade represents a 76.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP C Frank Bennett sold 85,089 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $79.23, for a total transaction of $6,741,601.47. Following the transaction, the executive vice president directly owned 80,554 shares of the company’s stock, valued at $6,382,293.42. The trade was a 51.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 616,371 shares of company stock valued at $46,406,452 in the last ninety days. Corporate insiders own 2.60% of the company’s stock.

Ionis Pharmaceuticals Stock Performance

IONS opened at $76.49 on Thursday. The stock has a market capitalization of $12.64 billion, a price-to-earnings ratio of -36.95 and a beta of 0.38. The company has a fifty day moving average of $74.43 and a 200 day moving average of $77.66. Ionis Pharmaceuticals, Inc. has a fifty-two week low of $32.00 and a fifty-two week high of $86.74. The company has a debt-to-equity ratio of 2.75, a quick ratio of 4.09 and a current ratio of 4.10.

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last posted its earnings results on Wednesday, April 29th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.29. The company had revenue of $246.00 million during the quarter, compared to analysts’ expectations of $195.57 million. Ionis Pharmaceuticals had a negative net margin of 30.91% and a negative return on equity of 58.65%. Ionis Pharmaceuticals’s quarterly revenue was up 86.4% on a year-over-year basis. During the same period last year, the company posted ($0.93) earnings per share. As a group, sell-side analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Barclays increased their price target on shares of Ionis Pharmaceuticals from $106.00 to $115.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. Royal Bank Of Canada increased their price objective on shares of Ionis Pharmaceuticals from $95.00 to $100.00 and gave the stock an “outperform” rating in a research note on Thursday, April 30th. HC Wainwright reissued a “buy” rating on shares of Ionis Pharmaceuticals in a research note on Wednesday. Stifel Nicolaus increased their price objective on shares of Ionis Pharmaceuticals from $73.00 to $77.00 and gave the stock a “hold” rating in a research note on Thursday, February 26th. Finally, Leerink Partners increased their price objective on shares of Ionis Pharmaceuticals from $102.00 to $104.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 3rd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Ionis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $100.90.

Check Out Our Latest Stock Report on Ionis Pharmaceuticals

Ionis Pharmaceuticals Profile

(Free Report)

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.